Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bandyopadhyay, Debabrata
MINT, NCT05799755: Myositis Interstitial Lung Disease Nintedanib Trial	Active, not recruiting	4	70	US	Nintedanib, OFEV, Placebo, Standard of Care	Rohit Aggarwal, MD, Boehringer Ingelheim	Myositis Associated Interstitial Lund Disease (MA-ILD)	07/25	12/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis May 2024 - Aug 2024 : Topline data for IPF Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF	Recruiting	3	576	Canada, US	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	06/25	06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis	Recruiting	3	698	Canada, US, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Progressive Pulmonary Fibrosis, Interstitial Lung Disease	11/27	11/27
PHINDER, NCT05776225: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection	Recruiting	N/A	200	US	Right heart catheterization (RHC)	United Therapeutics	Interstitial Lung Disease, Pulmonary Hypertension	04/25	06/25
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry Oct 2015 - Oct 2015:	Recruiting	N/A	3000	US		Duke University, Boehringer Ingelheim	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	01/28	01/28